Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.45 |
| ▸ | CDK4 | P11802 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 3/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.37 |
| ▸ | SYK | P43405 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701720 | 0.87 | HDAC1 (0.55) | CDK2CCNE1CDK4HDAC1 | |
| SCHEMBL701790 | 0.87 | CDK2 (0.47) | CDK2CCNE1CDK4HDAC1SRC | |
| SCHEMBL700146 | 0.85 | CDK2 (0.49) | CDK2CCNE1CDK4HDAC1SYK | |
| SCHEMBL13985109 | 0.84 | MAPT (0.41) | CDK2SYKGSK3B | |
| SCHEMBL702195 | 0.83 | CDK2 (0.62) | CDK2CCNE1CDK4HDAC1GSK3B | |
| SCHEMBL13984946 | 0.81 | MCHR1 (0.34) | HDAC1 | |
| SCHEMBL7977600 | 0.78 | CDK2 (0.53) | CDK2CCNE1CDK4HDAC1GSK3B | |
| SCHEMBL700180 | 0.78 | CDK2 (0.49) | CDK2CCNE1CDK4HDAC1SRC | |
| SCHEMBL699362 | 0.77 | CDK2 (0.43) | CDK2CCNE1CDK4SYKGSK3B | |
| SCHEMBL700312 | 0.76 | HDAC1 (0.51) | CDK2CCNE1CDK4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | CDK2 16/4885CCNE1 75/4885CDK4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.